Literature DB >> 17595512

Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.

Johannes Rieger1, Brigitte Frank, Michael Weller, Wolfgang Wick.   

Abstract

BACKGROUND: Many tumor cells are resistant to Apo2L/TRAIL-induced apoptosis in the absence of inhibitors of protein synthesis. Apo2L/TRAIL, in addition to induction of apoptosis, may therefore also activate survival pathways.
METHODS: Here we investigated whether such survival pathways mediate resistance to Apo2L.0-induced apoptosis in human glioma cells.
RESULTS: Apo2L.0 induced the phosphorylation of ERK1/2, but not of Akt. This effect was unaffected by caspase inhibition. Inhibitors of protein synthesis, PI3 kinase, ERK kinase, NF-kappaB or casein kinase 2 sensitized for Apo2L.0-induced apoptosis to a different extent in a panel of human malignant glioma cell lines. However, none of the sensitizers overcame resistance mediated by ectopic expression of the viral caspase 8 inhibitor, crm-A. Primary glioma cultures were almost completely resistant to Apo2L.0-induced cell death even in the presence of the inhibitors. Caspase-8 was expressed in these cells whereas only weak expression of DR5 was detected. Transient expression of DR5 conferred sensitivity to Apo2L.0.
CONCLUSION: These data challenge the view that specific cell lines harbour specific mechanisms of resistance to Apo2L/TRAIL. Weak expression of DR5 in primary glioma might limit the therapeutic application of Apo2L/TRAIL in human glioblastoma patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17595512     DOI: 10.1159/000104150

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  11 in total

1.  APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.

Authors:  Günter Eisele; Patrick Roth; Kathy Hasenbach; Steffen Aulwurm; Fabian Wolpert; Ghazaleh Tabatabai; Wolfgang Wick; Michael Weller
Journal:  Neuro Oncol       Date:  2010-12-22       Impact factor: 12.300

2.  Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.

Authors:  Navid Redjal; Yanni Zhu; Khalid Shah
Journal:  Stem Cells       Date:  2015-01       Impact factor: 6.277

3.  Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.

Authors:  Motoo Nagane; Saki Shimizu; Eiji Mori; Shiro Kataoka; Yoshiaki Shiokawa
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

4.  Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.

Authors:  Seong Muk Kim; Ji Sun Woo; Chang Hyun Jeong; Chung Heon Ryu; Jae-Deog Jang; Sin-Soo Jeun
Journal:  Stem Cells Transl Med       Date:  2014-01-16       Impact factor: 6.940

5.  Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.

Authors:  Marianela Candolfi; Kader Yagiz; David Foulad; Gabrielle E Alzadeh; Matthew Tesarfreund; A K M Ghulam Muhammad; Mariana Puntel; Kurt M Kroeger; Chunyan Liu; Sharon Lee; James F Curtin; Gwendalyn D King; Jonathan Lerner; Katsuaki Sato; Yohei Mineharu; Weidong Xiong; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Cancer Res       Date:  2009-07-01       Impact factor: 12.531

Review 6.  Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

Authors:  Marianela Candolfi; Kurt M Kroeger; A K M G Muhammad; Kader Yagiz; Catherine Farrokhi; Robert N Pechnick; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

7.  Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.

Authors:  Kaoru Tamura; Hiroaki Wakimoto; Aayush S Agarwal; Samuel D Rabkin; Deepak Bhere; Robert L Martuza; Toshihiko Kuroda; Randa Kasmieh; Khalid Shah
Journal:  Mol Ther       Date:  2012-08-28       Impact factor: 11.454

8.  Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.

Authors:  Shawn Hingtgen; Xianghui Ren; Ernie Terwilliger; Marie Classon; Ralph Weissleder; Khalid Shah
Journal:  Mol Cancer Ther       Date:  2008-11       Impact factor: 6.261

9.  Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.

Authors:  Irina Nesterenko; Simone Wanningen; Tugba Bagci-Onder; Maarten Anderegg; Khalid Shah
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related Proteins.

Authors:  Zhenzhen Zhang; Tingmei Ye; Xueting Cai; Jie Yang; Wuguang Lu; Chunping Hu; Zhigang Wang; Xiaoning Wang; Peng Cao
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.